Kornimate/medical-research-clean huggingface dataset:
dietary sugar absorptive phenotype for prediction of weight loss outcome

Conditions: Obese; Healthy; Bariatric Surgery Candidate

Summary: this study is trying to determine whether the success of bariatric surgery can be predicted by evaluating the dietary sugar absorptive characteristics in the small intestine and if there is any gene expression change on the dietary sugar absorptive characteristics.


Eligibility criteria:
inclusion criteria: - obese patients (bmi ≥ 30) scheduled for bs undergoing standard of care screening egd, or lean bs-naïve individuals (bmi ≤ 25) subjected to egd for routine clinical indications as part of standard care. exclusion criteria: * adults unable to consent, including non-english speakers. * pregnant women because endoscopy is a risk factor. all patients of childbearing age undergo history as well as urine pregnancy test as a standard of care prior to undergoing endoscopy as the procedure is performed under anesthesia. * prisoners. * subjects with preexisting conditions (e.g., bleeding at the time of the procedure, suspected perforation during the standard-of-care procedure) will be excluded from the study at the time of the endoscopy. * have a contraindication to endoscopy. * a history of surgery on the stomach or small intestine. * type 1 diabetes (clinical diagnosis and/or positive glutamic acid decarboxylase antibodies). * using weight loss medications. * active malignancy within the last 5 years.
study of tisagenlecleucel in combination with ibrutinib in r/r diffuse large b-cell lymphoma patients

Conditions: Diffuse Large B-cell Lymphoma

Summary: a multi-center, open-label, phase ib study to evaluate the safety and tolerability of the administration of tisagenlecleucel in combination with ibrutinib in patients with r/r dlbcl who have received two or more lines of systemic therapy, including an anti-cd20 and anthracycline based chemotherapy, and who have progressed after or are not candidates for asct.


Eligibility criteria:
inclusion criteria: 1. confirmed dlbcl as per the local histopathological assessment. 2. relapsed or refractory disease having received 2 or more lines of systemic therapy, including anti-cd20 and anthracycline based chemotherapy, and either having progressed after (or relapsed after) asct, or being ineligible for or not consenting to asct. 3. measurable disease at time of enrollment. 4. eastern cooperative oncology group (ecog) performance status that is either 0 or 1 at screening. 5. adequate renal, liver, and bone marrow, organ function, and minimum level of pulmonary reserve. exclusion criteria: 1. patients with richter's transformation, burkitt's lymphoma, and primary dlbcl of the cns. 2. prior anti-cd19 directed therapy. 3. prior gene therapy. 4. prior adoptive t cell therapy. 5. prior ibrutinib therapy within the 30 days prior to screening. 6. patients with active cns involvement are excluded, except if the cns involvement has been effectively treated and provided that local treatment was \> 4 weeks before enrollment. 7. prior allogeneic hsct 8. . significant cardiac abnormality including history of myocardial infarction within 6 months prior to screening as detailed in the study protocol. other eligibility criteria may apply.

Keywords: lymphoma diffuse large b-cell lymphoma dlbcl r/r diffuse large b-cell lymphoma relapsed/refractory dlbcl ctl019 tisagenlecleucel ibrutinib
ultrasonic diagnosis of tear of the anterior superior labrum of the hip

Conditions: Acetabular Labrum Tear

Summary: the patients were divided into two groups, one group was a suspected hip joint anterior superior labrum tear, and the other group was a non-hip joint disease. the patients received conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip mri for surgery perform diagnostic power test for the gold standard.

the patients were divided into two groups, one group was patients with suspected anterior superior labrum tear, and the other group was patients with non-hip joint diseases. routine ultrasound diagnosis of the hip, contrast-enhanced ultrasound, and high-resolution single hip mri were performed. for patients undergoing hip arthroscopic surgery after diagnostic occlusive treatment, the results of arthroscopic exploration are used as the diagnostic gold standard. a tear detected during the operation was judged to be positive, and a tear not detected was judged to be negative. for patients who have not undergone hip arthroscopic surgery after the closure treatment, if the mri of the hip is performed, the mri result is the gold standard. the diagnosis of tearing was judged as positive, and the undiagnosed tearing was judged as negative. this study was used to compare (1) the diagnostic efficacy of hip joint contrast-enhanced ultrasound and high-resolution single hip mri in patients with suspected anterior superior labrum tear. (2) comparison of the diagnostic efficiency of contrast-enhanced hip joint ultrasound and conventional ultrasound in patients with suspected anterior superior labrum tear. (3) in the process of judging the hip joint anterior superior labrum tear by conventional ultrasound and contrast-enhanced ultrasound of the hip joint, the consistency of repeated readings and the comparison of the consistency between readers.

Eligibility criteria:
inclusion criteria: case group inclusion criteria (1) age is greater than or equal to 18 years old (2) patients with preoperative ultrasound examination for clinically planned hip joint anterior superior labrum tear (3) the patient can understand and sign the informed consent form . control group inclusion criteria 1. age is greater than or equal to 18 years old 2. patients who come to the ultrasound department of our hospital for treatment of non-hip joints at the same time 3. the patient can understand and sign the informed consent form exclusion criteria: case group exclusion criteria 1. mental conditions are not allowed 2. adhesives that are allergic to any known . control group exclusion criteria (1) mental conditions are not allowed (2) adhesives that are allergic to any known (3) past and current diseases of other hip joint diseases
impact of a personalized case management program for the follow-up of moderate and severe asthma patients on exacerbations, health resource use and asthma control: percasthma study

Conditions: Asthma; Case Management; Telemedicine

Summary: the goal of this randomized clinical trial is to learn about the impact of the implementation of an intervention-based case management follow-up program during periods of clinical worsening or poor adherence in patients with moderate and severe asthma. patients will be randomized into two arms: a case management follow-up group and a control group that will follow-up according to routine care practice. a single masking (outcomes assessor) was performed. researchers will compare the response on exacerbations, health resource use and asthma control between the two groups during a one-year follow-up. outcomes on pulmonary function, quality of life, adherence to treatment, pulmonary inflammation parameters and systemic corticosteroid use will also be studied. additionally, other baseline clinical characteristics and events of the previous year will be collected retrospectively for all patients. the study was evaluated and approved by a local ethics committee. all study participants will receive an asthma education session with review of inhaler technique and training in the use of self-management action plans. only participants in the case management follow-up group will periodically send asthma control (act) and adherence (tai) questionnaires to the case manager. if not completed, the case manager will contact the patient by telephone to determine the degree of asthma control and adherence. the case manager will also monitor the withdrawal of drugs on the electronic prescription. the patient will contact the case manager via a mobile app, phone or email if needed due to worsening symptoms or need for self-management support. with this information, the case manager will make decisions based on personalized medical instructions prepared by the pulmonologist at the baseline visit, which will be reviewed according to evolution.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * previous diagnosis of bronchial asthma according to gema 5.4 criteria. • follow-up for at least 6 months in an asthma unit and absence of relevant uncontrolled comorbidities. * classified as moderate or severe asthma according to therapeutic step at the beginning of the study, as defined by gema 5.4. * signed informed consent form. exclusion criteria: * simultaneous presence of other diseases that may simulate asthma symptoms (copd, left heart failure, functional dyspnea/hyperventilation syndrome, inducible laryngeal obstruction...). * severe psychosocial problems or any other clinical situation that prevents the signature of the informed consent and/or the follow-up proposed in the study. * lack of minimum technological knowledge for the use of monitoring tools.

Keywords: asthma case manager telemedicine exacerbations
establishment of prevention and control system of central nervous system infection

Conditions: Central Nervous System (CNS) Infection; Encephalitis; Meningitis

Summary: central nervous system (cns) infection is a common nervous system acute and severe disease, mainly manifested as encephalitis, meningitis and meningoencephalitis, but also manifested as brain abscess and brain granuloma et al. the basis for the diagnosis of cns infection lies in the detection of pathogens from brain parenchyma or cerebellar spinal fluid (csf). however, csf is relatively difficult to obtain and the sample size is small, which limits the rapid and definite diagnosis of cns infection pathogens. in addition, cns infection usually has non-specific clinical manifestations, so it is difficult to identify the pathogen for about half of cns infection. metagenomic next generation sequencing (mngs) and biochip technology provide new means to identify the pathogens of cns infection. this study analyzes the incidence and epidemic characteristics of cns infection in china, to standardize the csf sample processing process, shorten the detection time, increase the sensitivity and specificity of pathogen detection, reduce the detection cost, identify the common pathogens of cns infection, and establish a standardized rapid diagnosis system, effective prevention and control system.


Eligibility criteria:
inclusion criteria: * clinical suspected encephalitis or meningitis; onset time within 1 month; modified rankin scale (mrs) \< 2 points before onset; informed consent of patients; patients who can not express their personal wishes due to aphasia, disturbance of consciousness and other reasons need to obtain the informed consent of their authorized relatives. exclusion criteria: * non.

Keywords: central nervous system (cns) infection diagnosis pathogen metagenomic next generation sequencing
the evaluation of single acupoint therapy to acute low back pain

Conditions: Acupuncture; Acute Low Back Pain

Summary: low back pain is the leading course of disability , affecting patients' health and work. recently, studies have reveal the fact that patients get insufficient physical activity and easily let acute stage turn to chronic type. although acupuncture for low back pain is worldwide popular, the mechanism of single acupoint for low back pain is still unclear. therefore, the aim of this study is the investigators choose the most frequent used acupoint and modified single acupoint method to assess the efficacy of single acupoint to acute low back pain.

low back pain is the leading course of disability , affecting patients' health and work. according to the study in 2013, 8.9 percent people of the world experienced over three months low back pain. recently, studies have reveal the fact that patients get insufficient physical activity and easily let acute stage turn to chronic type. although acupuncture for low back pain is worldwide popular, the mechanism of single acupoint for low back pian is still unclear. therefore, the investigators choose the most frequent used acupoint and modified single acupoint method to assess the efficacy of single acupoint to acute low back pain. the investigators would like to compare the efficacy of the modified bladder 40 (bl40) acupuncture to single acupoint through statistical analysis. the investigators expect that all group will alleviate low back pain. however, treatment group will have statistical difference compared with control groups. the aim of this study is the investigators choose the most frequent used acupoint and modified single acupoint method to assess the efficacy of single acupoint to acute low back pain.

Eligibility criteria:
inclusion criteria: * low back pain,duration \< 1 month * accept subject consent exclusion criteria: * without x ray or mri image * severe trauma , fracture or spondylosis found from image ,progression neurological symptoms suspected from central nerve system, rheumatic disease, fever or infection is suspected ,weight or cancer history , pregnancy and psychiatric disorder or not able to communication .

Keywords: acute low back pain bl40 extra meridian 32 (em32) acupuncture
a trial of shr-3792 injection in patients with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: the study is being conducted to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of shr-3792 injection monotherapy for patients with advanced solid tumors, and to explore the reasonable dosage of shr-3792 injection monotherapy for patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. subjects with ability to understand and voluntarily agree to participate by giving written informed consent form for the study. 2. patients with unresectable recurrent or metastatic solid tumors. 3. there is at least one lesion that could be measured. 4. an eastern cooperative oncology group (ecog) performance status (ps) score of 0 or 1. 5. adequate organ functions as defined. 6. life expectancy ≥ 3 months. exclusion criteria: 1. patients with known active central nervous system (cns) metastases. 2. subjects with other malignancy in five years before the first dose. 3. patients with tumor-related pain that cannot be controlled as determined. 4. patients with serious cardiovascular and cerebrovascular diseases. 5. uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion. 6. patients with severe infections. 7. history of immunodeficiency. 8. history of autoimmune diseases. 9. active infection. 10. pregnant or nursing women. 11. known history of serious allergic reactions to the investigational product or its main ingredients.
the symchro - observational registry study for symbotex™ composite mesh in ventral hernia repair

Conditions: Ventral Incisional Hernia

Summary: the aim of this observational registry study is to assess the short- and long-term clinical outcomes following the use of symbotex™ composite mesh in primary and incisional abdominal wall hernia surgeries by open or laparoscopic approach, according to the instruction for use (ifu).

this is an observational multicenter registry study. one hundred consecutive, adult patients scheduled for primary and incisional abdominal wall hernia surgeries using symbotex™ composite mesh will be reported in the clubhernie online database, with standard data captured of all preoperative, perioperative and post-operative data, for patient's outcomes measurements. primary objective: evaluate the incidence of peri-operative and post-operative complications, with postoperative evaluations occurring, at discharge , 1 week (d1 and d8 follow up), 1 month (d30 follow up), 1 year and 2 year follow up after primary and incisional abdominal wall hernia surgeries using symbotex™ composite mesh by open or laparoscopic approach (such as anticipated device related complications such as pain, recurrence, complications related to adhesions, wound complications, other postoperative complications, (sae). this online database consists of a systematic and consecutive data entry of all patients treated for inguinal hernia and ventral hernia by the 30 french surgeon members, with standard data captured of all preoperative, perioperative and post-operative data. the database is required to be completed anonymously. quality data control of all data captured into the online database will be performed by coherence analysis by club hernie authorized representative;a statistical analysis plan will be developed by covidien. study reported device-related events will be reviewed periodically to assess for any potential trends

Eligibility criteria:
inclusion criteria: * the first one hundred consecutive adult patients scheduled for primary and incisional abdominal wall hernia surgery by club hernie members surgeons using symbotex™composite mesh ;- all patients regardless of gender ≥ 18 years of age presenting with ventral hernias. * patients will be informed by surgeon with a written information notice of the nature of the observational registry study. exclusion criteria: * no exclusion criteria outside the product ifu

Keywords: hernia symchro sofradim registry symbotex
obstructive sleep apnea - patient specific factors, success rate and compliance

Conditions: Sleep Apnea, Obstructive

Summary: obstructive sleep apnea (osa) is a condition where the patient's breathing cease during sleep due to collapse of the oro-pharynx. the consequences are reduced quality of sleep, increased risk for developing cardiovascular disease and increased risk of accidents caused by daytime sleepiness. among norwegians 30-65 yrs, the prevalence of osa are estimated to 16%. the golden standard in osa-treatment is continuous positive airway pressure (cpap). this is effective and must be used for life. however, cpap-treatment might be uncomfortable for the patient, with poor compliance as a result. an alternative is mandibular advancing splints (mas), which is perceived as less troublesome and may initiate higher compliance. through mapping of patient characteristics, the researchers investigate which patient-type benefits most from two different treatment-devices. the aim of the study is to assess how the mas treatment differ from the cpap treatment in respect to efficacy, compliance and impact on health related quality of life among patient diagnosed with mild/moderate osa. all osa patients referred to the ear- nose- throat-department (ent) at university hospital, northern-norway (unn) and st.olavs hospital were invited to participate in the study. the sample size at completion of the study should be 140 patients. participants in the trial were randomly allocated to the two treatment groups, and assessed after 4 and 12 months of treatment. data were collected through anamnesis, clinical examination, clinical photos, radiographs and questionnaires concerning general health related quality of life (sf36), oral health, cognitive aspects (hads), sleep quality (psqi), daytime sleepiness (epworth's sleepiness scale) and compliance.


Eligibility criteria:
inclusion criteria: * 10 ≤ apnea-hypopnea-index ≤ 30 at baseline * subjective symptoms of osa * ability of at least 5mm protrusion of the mandible * accept randomization of treatment modality * accept to fill in the questionnaires * accept to attend at planned consultations exclusion criteria: * primarily central sleep apnea * known temporomandibular dysfunction (tmd) * mental instability * drug abuse * extensive usage of sedative medication which disqualifies for osa-treatment * extensive gag-reflex or claustrophobia * inadequate dental support (\< 10 teeth in lower jaw) * inadequate periodontal support (no tooth mobility \> miller grade i) * anatomical abnormalities in the nasal cavity or oro-pharynx that disqualifies the use of cpap and/or mas * anatomical abnormalities which should be surgically corrected before treatment with cpap and/or mas * severely compromised general health condition * pregnancy * general health issues that disqualifies the use of cpap and or mas

Keywords: continuous positive airway pressure mandibular advancing splint efficacy compliance health related quality of life randomized controlled trial snoring mandibular advancing appliance mandibular advancing device humans quality of life sleep apnea, obstructive
dose-ranging efficacy and safety study of topical rapamycin cream for facial angiofibroma associated with tuberous sclerosis complex

Conditions: Facial Angiofibroma; Tuberous Sclerosis

Summary: the study aims to compare the safety and efficacy of two different strengths of rapamycin cream, topical and placebo over 26 weeks in the treatment of facial angiofibroma (fa) associated with tuberous sclerosis complex (tsc).

topical rapamycin has previously been used to treat fa associated with tsc, reducing erythema, papule size, while flattening lesions and improving skin texture. topical rapamycin has been reported to be well tolerated. the efficacy and safety of a topical rapamycin cream at two strengths (0.5% and 1.0%) will be assessed during a 26 week double-blind treatment phase with assessments made at clinical visits at baseline, 2, 8, 14, 20 and 26 weeks, and at follow-up (4 weeks after the last dose of study drug).

Eligibility criteria:
inclusion criteria: 1. male and female patients aged ≥ 6 years and ≤ 65 years on the day informed consent is obtained 2. patients diagnosed with tsc based on the clinical diagnostic criteria of international tuberous sclerosis complex consensus conference 2012 and presenting visible facial angiofibroma 3. an fa severity score of 2 or 3 on the iga scale 4. patients or their legal representatives capable of understanding the explanation of the clinical trial and who give written informed consent for participation 5. patients or their legal representatives able to maintain patient diaries following the instructions of the investigator or sub-investigator exclusion criteria: 1. patients who cannot carry out the treatment plan or follow-up assessment 2. patients with serious skin lesions such as erosions or ulcers 3. patients with known hypersensitivity to any component of the study product 4. patients who have received rapamycin/sirolimus, everolimus, or temsirolimus within 3 months of enrolment 5. patients who received laser therapy or surgical therapy within 6 months prior to trial enrolment 6. patients who participated in any other clinical trial within 3 months prior to the day of enrolment 7. patients judged unsuitable for this clinical trial by the investigator or sub-investigator 8. pregnant or lactating females 9. sexually active females of childbearing potential not using adequate contraception and sexually active males not using adequate contraception 10. patients with immune dysfunction or receiving any form of immunosuppression 11. patients with severe fa, with a score of 4 on the iga scale 12. patients with an fa severity score of less than 2 on the iga scale
comprehensive frailty assessment

Conditions: Myeloma, Multiple; Paraproteinemias; Hematologic Neoplasms

Summary: the purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). fitness is a way of measuring a patient's current quality of health. with surveys, questionnaires and blood tests, we hope to create a tool that will give a good picture of patients' ability to tolerate treatment. in the future, we hope to devise the best treatment for a patient based on their "fitness".


Eligibility criteria:
inclusion criteria: * patients with a plasma cell dyscrasia and/or any patient receiving a stem cell transplant for a hematologic malignancy at the ohio state university * at least 18 years of age exclusion criteria: - any medical or psychiatric condition that would make it difficult for the patient to comply with study procedures.

Keywords: myeloma mgus (monoclonal gammopathy of undetermined significance) amyloidosis stem cell transplant